Searched for
GENERIC MEDICINES
Parl panel for early conclusion of India-US trade pact, tariff exemptions on key goodsThe panel suggested the commerce department prepare a time-bound roadmap to achieve the objectives of the Mission 500 initiative by promoti...- IPA seeks to regularise 'legacy' drugsThe Indian Pharmaceutical Alliance seeks to regularize many drugs. These drugs have been marketed for years without central approval. Examp...
- Dr Reddy's Laboratories launches generic Sugammadex injection in the United StatesDr Reddy's Laboratories has launched its generic Sugammadex injection in the United States. This new product reverses muscle relaxant effec...
- India pharma sector to miss 2030 sales target amid tariff and shipping woes, trade body saysIndia's pharmaceutical industry is expected to reach$80-90 billion by 2030, well below its earlier$130 billion target, as U.S. tariff uncer...
- MOFSL stays bullish on Sun Pharma; sees 16% upside on innovation pipelineSun Pharma's June quarter results met analyst expectations, signaling future growth. The company is expanding its specialty and innovative ...
- Sun Pharma Q1 Results: Profit rises 27% YoY to Rs 2,895 crore; revenue climbs 10.5%Sun Pharma Q1 Results: Sun Pharma reported a 27% YoY rise in Q1 net profit to Rs 2,895 crore, while revenue grew 10% to Rs 15,300 crore, dr...
- Tariff on generic drugs: Loud announcement, little consequence? 7 pharma stocks with upside potential of up to 31%The threat of a US tariff on Indian pharma is no longer a vague fear; or at least that is what President Trump wants us to believe. There i...
- Pharma mutual funds top return charts across horizons. Should investors chase the rally or stay cautious?Pharma mutual funds are leading returns in CY2026, driven by strong earnings, defensive demand, and US export growth. Despite recent outper...
- US tariff proposal wake-up call for Indian pharma to diversify, innovate: ExpertsUS pharma tariffs: Experts have urged a shift towards global diversification and prioritising innovation for Indian pharma to lessen market...
- Trump's 200% generic drug tariff threat puts $9.7 billion Indian pharma exports at risk; industry says reshoring not practicalUS President Trump's proposed tariffs on imported generic drugs will not immediately affect Indian drugmakers. Indian companies export sign...
- Tariff hike by US will only increase drug prices: Dr Reddy's CEOUS tariff increases on generic medicines will lead to higher drug prices in India. Dr Reddy's Laboratories CEO Erez Israeli stated relocati...
- Tariffs alone will not produce sustainable generic medicine in US: IPAThe Indian Pharmaceutical Alliance believes tariffs alone will not build US generic drug manufacturing. Broader reforms are needed for fair...
- Generic drugmaker Sandoz to engage with US after Trump tariff threatUS President Donald Trump threatened steep tariffs on generic drugmakers. He stated medicines must be manufactured locally or face signific...
- Indian pharma firms may yet survive Trump's 200% tariff bombshellDonald Trump's proposed up to 200% tariff on generic drug imports has raised concerns for Indian pharma companies, but industry experts say...
- 200% Trump tariff shock? India’s cheap pills may still beat US rivalsUS President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could put pressure on India's pharmaceutical expor...
- Trump’s 100% generic drug duty threatens US low-cost supplyPresident Donald Trump has given generic drugmakers two years to shift manufacturing to the US or face 100% import tariffs from August 2028...
- Trump's Generic Drug Tariffs Explained: What it means for Indian pharma before the 200% stormTrump's generic drug tariffs plan provides Indian drugmakers a two-year duty-free window. This allows companies time to reassess manufactur...
- Trump's 200% drug tariff plan: Is India's pharma industry about to face an economic storm?The United States is set to implement a phased approach to tariffs on generic drug imports, beginning at zero percent and escalating to one...
- Trump announces new generic drugs tariff plan: No tariffs for 2 years, then 100%, and then 200%For Indian exporters, the two-year tariff-free period offers additional time to reassess supply chains and investment plans. While the imme...
- Sun Pharma, Cipla & other pharma stocks shed over 2% as Trump announces up to 200% tariffs on generic drugs from 2028Pharma stocks, including Sun Pharma, Cipla, Lupin and Dr Reddy's, fell up to 2.5% after US President Donald Trump announced a phased tariff...
Load More
